Clinical Trial Update: A Patient Registry Study for Patients Treated With Voretigene Neparvovec in US

View source ↗

Summary

This clinical trial registry entry reports a completed U.S. patient registry study of Voretigene Neparvovec (Luxturna) for biallelic RPE65 mutation-associated r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rpe65-related Retinal Dystrophy

Drugs mentioned

• Voretigene Neparvovec (voretigene neparvovec)

Snippet

Sponsor: Spark Therapeutics, Inc. | Conditions: Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy | Status: COMPLETED